Millennium | Clinicians | Oncology | VELCADE | Safety: Peripheral Neurophathy

	MULTIPLE MYELOMA



	MECHANISM
	LANDMARK PHASE 3 APEX TRIAL
	SURVIVAL
	TREATMENT TIMING
	RENAL IMPAIRMENT
	LENGTH OF THERAPY
	RETREATMENT
	SAFETY PROFILE
-	Peripheral Neuropathy
-	Transient Thrombocytopenia
	DOSE MODIFICATION GUIDELINES
	HANDLING AND ADMINISTRATION
	IMPORTANT SAFETY INFORMATION
	REIMBURSEMENT
	ADDITIONAL INFORMATION
	REFERENCES

PERIPHERAL NEUROPATHY

Manageable and Generally Reversible¹

Mild preexisting peripheral neuropathy (less than grade 2) was not predictive of treatment-emergent peripheral neuropathy in APEX

–	69% of all patients entered the APEX trial with preexisting peripheral neuropathy*

*630 patients in APEX were assessed at baseline for presence of peripheral neuropathy.¹

^†National Cancer Institute Common Terminology Criteria (NCI CTC), Version 2.0., June 1999²

Please click here to view additional important safety information.

For full Prescribing Information click here. (pdf) (74KB)

For further information about VELCADE^® (bortezomib) for Injection, call 1-866-VELCADE (U.S. clinicians only).